EHA Takeaways for Covered Names

Research evidence excerpt

EHA Takeaways for Covered Names

at EHA 2026 (data cut-off March 31, 2026), ORR per

mIWG-MRT-ECNM criteria improved to 65% (vs. ~57% at the topline), while the pure

pathological response (PPR) ORR reached 81% (vs. ~80% at the topline). New durability

metrics showed an impressive 12-mos PFS rate of 79% and 12-mos OS rate of

87% (median duration of PFS and OS were immature at 62 weeks of median follow-

up). Reductions in objective disease measures, including a ≥50% reduction in serum

tryptase (89%), MC burden (89%), and KIT D816V VAF (91%), were in-line with topline

reporting. On the safety front, nearly all TRAEs were in-line with the topline, although

neutropenia ticked up slightly (now 31%, previously 30%). We note one additional patient

experienced Gr 3 transaminase elevation (now n=2), with this patient discontinuing

treatment while the original reported case resolved with dose reduction. A more detailed

review of pathobiology data highlight rapid improvements in bone marrow characteristics,

observed as early as eight weeks, with ~1/3 of patients achieving undetectable KIT

D816V levels in bone marrow.

are intrigued by CGT1145, a novel JAK2 V617F inhibitor with >100-fold selectivity ◦We

for JAK2 V617F (which is strongly associated with myeloproliferative neoplasms or

MPNs) over WT JAK2. Recall that CGT1145 demonstrated dose-dependent reductions

in spleen size in a mouse model of JAK2 V617F splenomegaly, with the 50 mg/kg

BID dose comparable to ruxolitinib activity. Treatment with CGT1145 also led to spleen

weight normalization, decreased erythroid precursor accumulation in the spleen, and

normalization of hematological parameters in a mouse model of JAK2 V617F-driven

MPN. The EHA 2026 poster was largely a rehashing of previous preclinical datasets, with